

Sjogren's Syndrome

Background

1. Definitions

- Chronic autoimmune disorder characterized by lymphocytic destruction of exocrine glands
- Frequently results in xerostomia and xerophthalmia

2. General information

- Underdiagnosed due to insidious onset and varied clinical presentation
- Associated with HLA-DR

Pathophysiology

1. Pathology of disease

- Chronic autoimmune response against epithelial cells of exocrine glands
- B lymphocyte dysregulation / hyperactivity plays major role
- Histological hallmark is B and T cell lymphocytic infiltration of exocrine glands

2. Incidence/prevalence

- Second most common rheumatologic disorder in the US behind fibromyalgia (1st) and RA (3rd)
- Occurrence in association with another connective tissue dz: 50-60%
- Affects 1-2 million people in US
- Female-to-male ratio: 9:1
- Peak incidence in 4th and 6th decades of life

3. Risk factors

- Female >40 yo
- Preexisting autoimmune dz
- Family Hx

4. Morbidity/mortality

- Morbidity
 - Most cases mild
 - Chronic keratoconjunctivitis
 - Corneal ulcers
 - Extraglandular dz
 - Affects 25-30%
 - Kidney, liver, lung, skin
 - Multiple dental caries, tongue fissures, oral candidiasis
 - Fatigue
 - Non-Hodgkin's lymphoma eventually develops in 2.5-5%
 - Depression, cognitive impairment
- Mortality
 - Primary dz
 - Normal life expectancy
 - Secondary dz
 - Increased mortality from associated autoimmune disorder

Diagnosics

1. History/symptoms

- Dryness of
 - Mouth (98%)
 - Difficulty speaking, eating, swallowing
 - Eyes (93%)
 - Dryness, grittiness, pruritus, foreign body sensation
 - Required for clinical Dx
 - Skin
 - Dryness, pruritus
 - Vagina
 - Pruritus, dyspareunia
 - Nose
 - Trachea
 - Cough
- Fatigue
- Arthralgias (37-75%)
- Myalgias, fibromyalgia
- Raynaud's phenomenon (16-28%)
- Autoimmune thyroiditis (15-33%)

2. Physical exam

- Keratoconjunctivitis, conjunctival injection, corneal clouding (severe Dz)
- Decreased saliva, dry mucous membranes (with fissuring, ulceration) and multiple dental caries
- Vasculitis
 - Palpable purpura, urticaria or glomerulonephritis
- Lymphadenopathy
- Polyneuropathy, peripheral neuropathy
- Parotid gland enlargement, tenderness
- Signs of other autoimmune disorders (in 2° SS: RA, SLE)

3. Diagnostic testing

- Majority of confirmatory tests done outside PCP office
- Ocular evaluation
 - **Schirmer test**
 - Measures tear production
 - Test strip of # 41 Whatman filter paper is placed in lateral third of lower eyelid to measure tear formation
 - Normal test: 15 mm of wet filter paper in 5 min
 - Positive test: < 5 mm in 5 min
 - **Rose bengal staining**
 - Identifies KCS, requires ophthalmologist
 - Instill 1% rose bengal in the eye, slit lamp exam
 - Rose bengal stains devitalized cornea / conjunctiva
- Oral
 - Dental exam
 - Sialometry
 - Salivary flow rate measured by spitting into test for 15 minutes
 - Abnormal: unstimulated flow rate <1.5 mL/15 min

- Contrast sialography
 - Visualize salivary glands with injected contrast
 - Salivary scintigraphy
 - Insensitive but highly specific
 - Evaluates salivary gland function
 - Minor (lip) salivary gland biopsy
 - Can confirm SS or exclude other Dx
 - Laboratory
 - Specific (% positive in SS)
 - ANA: 55-97%
 - Anti-SS-A/Ro: 16-70%
 - Anti-SS-B/La: 7-50%
 - RF: 32-90%
 - Systemic
 - CBC, ESR, LFTs, TSH, BUN/Cr, UA
 - Other studies
 - CT scan if progression to lymphoma suspected
4. Revised International Classification Criteria for Sjogren Syndrome
- Dx requires presence of 4 of 6 criteria below and must include criterion #5 or #6
 1. Ocular symptoms
 - Dry eyes >3 mths
 - Foreign body sensation in the eyes
 - Use of artificial tears >3x per day
 2. Oral symptoms
 - Dry mouth >3 mths
 - Chronic swelling of salivary glands
 - Use of liquids to facilitate swallowing
 3. Ocular signs
 - Schirmer test <5 mm/5 mins, performed without anesthesia
 - Positive vital dye staining
 4. Oral signs
 - Abnormal salivary scintigraphy
 - Abnormal parotid scintigraphy
 - Unstimulated salivary flow <1.5 mL in 15 mins
 5. Positive salivary gland biopsy
 6. Antibody screen (anti-SS-A or anti-SS-B)
- Exclusion criteria
- Past head and neck radiation Tx
 - Hepatitis C infection
 - AIDS
 - Pre-existing lymphoma
 - Sarcoidosis
 - Graft vs Host Dz
 - Anticholinergic drug use

Differential Diagnosis

1. Dry mouth
 - Diabetes
 - Head / neck irradiation
 - Meds
 - Anti-hypertensive, anti-cholinergic, psychotherapeutic
 - Psychogenic
2. Dry eyes
 - Chronic conjunctivitis or blepharitis, eyelid infections / abnormalities
 - Lifestyle (long driving, reading, computer use)
 - Environment (low humidity, smoke)
 - Meds
 - Anti-hypertensive, anti-cholinergic, psychotherapeutic
 - Hypovitaminosis A
3. Parotid enlargement
 - Viral
 - Mumps, EBV, HIV, HCV, coxsackie
 - Endocrine
 - Acromegaly, hypogonadism, testosterone deficiency / hypogonadism, diabetes
4. Systemic / extraglandular
 - Rheumatoid arthritis, SLE, scleroderma
 - Menopause
 - Multiple sclerosis
 - Lymphoma
 - Hepatitis
 - HIV
 - Sarcoidosis
 - Amyloidosis
 - Anxiety
 - Myopathies
 - Atopic disease

Therapy

1. Ocular dz
 - Moisture preservation and replacement methods
 - Preservative free artificial tears
 - Osmoprotective artificial tears
 - Lubricating ointments and methylcellulose inserts at night
 - Occlusion of puncta: collagen or silicone plugs (temporary), thermal / surgical (permanent)
 - Special goggles and glasses
 - Secretagogues: cholinergics
 - Pilocarpine 5 mg PO BID-QID
 - Cevimeline 30 mg PO TID
 - Contraindicated in asthma, angle -closure glaucoma, pregnancy

- Anti-inflammatory therapy
 - Topical steroids
 - Topical cyclosporine
 - Omega-3 essential fatty acids: topical or oral
- 2. Oral dz
 - Saliva substitutes: lozenges, rinses, sprays, swabs
 - Frequent dental exams with fluoride treatment
 - Secretagogues
 - Pilocarpine and cevimeline as above
 - Avoid diuretics, antihypertensives, antidepressants, antihistamines
 - Oral hygiene, humidifiers, adequate water intake
 - Sugar-free gum/hard candy with xylitol: 4-5 times per day
 - Treat oral candidiasis
- 3. Systemic dz
 - NSAIDs (arthralgias, myalgias, parotid pain)
 - Hydroxychloroquine 200 mg PO QD
 - Corticosteroids (severe joint Sx, vasculitis, renal dz)
 - Anxiolytics, hypnotics, antidepressants
 - Secretagogues, humidification, guaifenesin

Follow-Up

1. Referrals
 - Consider referral of patients with known or suspected Sjogren's to rheumatologist
 - Consider referral to ophthalmologist (eye exams) and dentist (oral exams)
 - Consider oral surgery consultation for lip biopsy
2. Admit to hospital
 - Decision based on severity of presenting symptoms

Prognosis

1. Primary dz
 - High morbidity, increased risk of lymphoma, but not in all-cause mortality
2. Secondary dz
 - High morbidity, increased risk of lymphoma, increased mortality
3. Increased risk of lymphoma
4. General
 - Usually stable exocrine function over time

Prevention

1. Early diagnosis and treatment
 - Prevent complications of dental caries, corneal ulceration, chronic oral infection and sialadenitis
 - Clinical surveillance for serious extraglandular / systemic complications
 - Avoid activities that cause dryness to control symptoms

References

1. Kruszka P and O'Brian R. Diagnosis and management of Sjogren's syndrome. *Am Fam Physician*. 2009;79(6):465-470.
2. Bowman SJ. Patient-reported outcomes including fatigue in primary Sjogren's syndrome. *Rheum Dis Clin North Am*. 2008 Nov;34(4):949-62.
3. Foulks GN. Treatment of dry eye disease by the non-ophthalmologist. *Rheum Dis Clin North Am*. 2008 Nov;34(4):987-1000.
4. Kassan S and Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren's syndrome. *Arch Intern Med*. 2004;164:1275-1284.
5. Moutsopoulos HM. "Chapter 317. Sjögren's syndrome". Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J: *Harrison's Principles of Internal Medicine*, 17th Edition: 2008.
6. Ramos-Casals M, Munoz S, Zeron PB. Hepatitis C virus and Sjogren's syndrome: trigger or mimic? *Rheum Dis Clin North Am*. 2008 Nov;34(4):869-84
7. Vitali C, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-558.
8. Voulgarelis M, Tzioufas AG, Moutsopoulos HM. Mortality in Sjogren's syndrome. *Clin Exp Rheumatol*. 2008 Sep-Oct;26(5 Suppl 51):S66-71.
9. Wu AJ. Optimizing dry mouth treatment for individuals with Sjogren's syndrome. *Rheum Dis Clin North Am*. 2008 Nov;34(4):1001-10.

Authors: Annalee Baker, MD, & Juan Jan Qiu, MD, *Penn State Hershey Medical Center, PA*

Editor: Michael Flanagan, MD, *Penn State Hershey Medical Center, PA*